SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 359.34 |
| Enterprise Value ($M) | 144.58 |
| Book Value ($M) | 198.91 |
| Book Value / Share | 2.68 |
| Price / Book | 1.81 |
| NCAV ($M) | 183.50 |
| NCAV / Share | 2.47 |
| Price / NCAV | 1.96 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.61 |
| Return on Assets (ROA) | -0.44 |
| Return on Equity (ROE) | -0.48 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 7.00 |
| Current Ratio | 7.00 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 214.76 |
| Assets | 230.17 |
| Liabilities | 31.26 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Bain Capital Life Sciences Opportunities IV, L.P. | 9.99 | ||
| 13D/A | Biotechnology Value Fund L P | 9.99 | -17.28 | |
| 13G/A | Deep Track Capital, LP | 6.98 | 31.57 | |
| 13G/A | Paradigm Biocapital Advisors LP | 9.60 | -30.37 | |
| 13G | Point72 Asset Management, L.P. | 5.70 | ||
| 13D/A | Logos Global Management LP | 5.80 | -23.86 | |
| 13G/A | Cormorant Asset Management, LP | 4.49 | 18.00 | |
| 13G/A | Kynam Capital Management, LP | 0.00 | -100.00 | |
| 13G/A | Janus Henderson Group Plc | 1.30 | -77.10 | |
| 13G | BlackRock, Inc. | 6.00 | 150.01 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 230,979 | 1,236,249 | 18.68 | |
| 152,233 | 933,891 | 16.30 | |
| 178,707 | 1,116,238 | 16.01 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| NVAX – Novavax, Inc. | NXTC – NextCure, Inc. |
| OGI – Organigram Holdings Inc. | OMGA – Omega Therapeutics, Inc. |
| OPK – OPKO Health, Inc. |
Financial data and stock pages provided by
Fintel.io